Tags

Type your tag names separated by a space and hit enter

Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency.
Arzneimittelforschung. 1993 Oct; 43(10):1060-3.A

Abstract

Oxerutins (Venoruton) and troxerutin (CAS 7085-55-4) are both mixtures of O-(beta-hydroxyethyl)-rutosides used for the treatment of chronic venous insufficiency. As di-O-(beta-hydroxyethyl)-rutosides and 7-mono-O-(beta-hydroxyethyl)-rutoside were found to be more active with regard to free radical scavenging compared to tri-O-(beta-hydroxyethyl)-rutoside the aim of this study was to compare oxerutins and troxerutin clinically. 12 female, post-menopausal patients with chronic venous insufficiency grade II participated in this double-blind study with random allocation to the treatment groups. They received 900 mg/day oxerutins or troxerutin for 12 weeks and were observed for 4 further weeks without treatment. Leg volumes (water displacement) and subjective symptoms (VAS, visual analogue scale) were evaluated before and following 2, 4, 8, 12 and 16 weeks. Both treatments were active in reducing leg volumes and in ameliorating subjective symptoms (mean volume reduction -167 +/- 157 ml x week). Volume reduction totalled to -261 +/- 154.2 ml x week for oxerutins and -73.2 +/- 97.1 ml x week for troxerutin. The difference is statistically significant (p = 0.04). The findings with subjective symptoms were in good accordance to the objective volume measurement. Oxerutins revealed a remarkable carry over effect.

Authors+Show Affiliations

Zyma GmbH, München, Fed. Rep. of Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8267669

Citation

Rehn, D, et al. "Comparison Between the Efficacy and Tolerability of Oxerutins and Troxerutin in the Treatment of Patients With Chronic Venous Insufficiency." Arzneimittel-Forschung, vol. 43, no. 10, 1993, pp. 1060-3.
Rehn D, Golden G, Nocker W, et al. Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency. Arzneimittelforschung. 1993;43(10):1060-3.
Rehn, D., Golden, G., Nocker, W., Diebschlag, W., & Lehmacher, W. (1993). Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency. Arzneimittel-Forschung, 43(10), 1060-3.
Rehn D, et al. Comparison Between the Efficacy and Tolerability of Oxerutins and Troxerutin in the Treatment of Patients With Chronic Venous Insufficiency. Arzneimittelforschung. 1993;43(10):1060-3. PubMed PMID: 8267669.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency. AU - Rehn,D, AU - Golden,G, AU - Nocker,W, AU - Diebschlag,W, AU - Lehmacher,W, PY - 1993/10/1/pubmed PY - 1993/10/1/medline PY - 1993/10/1/entrez SP - 1060 EP - 3 JF - Arzneimittel-Forschung JO - Arzneimittelforschung VL - 43 IS - 10 N2 - Oxerutins (Venoruton) and troxerutin (CAS 7085-55-4) are both mixtures of O-(beta-hydroxyethyl)-rutosides used for the treatment of chronic venous insufficiency. As di-O-(beta-hydroxyethyl)-rutosides and 7-mono-O-(beta-hydroxyethyl)-rutoside were found to be more active with regard to free radical scavenging compared to tri-O-(beta-hydroxyethyl)-rutoside the aim of this study was to compare oxerutins and troxerutin clinically. 12 female, post-menopausal patients with chronic venous insufficiency grade II participated in this double-blind study with random allocation to the treatment groups. They received 900 mg/day oxerutins or troxerutin for 12 weeks and were observed for 4 further weeks without treatment. Leg volumes (water displacement) and subjective symptoms (VAS, visual analogue scale) were evaluated before and following 2, 4, 8, 12 and 16 weeks. Both treatments were active in reducing leg volumes and in ameliorating subjective symptoms (mean volume reduction -167 +/- 157 ml x week). Volume reduction totalled to -261 +/- 154.2 ml x week for oxerutins and -73.2 +/- 97.1 ml x week for troxerutin. The difference is statistically significant (p = 0.04). The findings with subjective symptoms were in good accordance to the objective volume measurement. Oxerutins revealed a remarkable carry over effect. SN - 0004-4172 UR - https://www.unboundmedicine.com/medline/citation/8267669/Comparison_between_the_efficacy_and_tolerability_of_oxerutins_and_troxerutin_in_the_treatment_of_patients_with_chronic_venous_insufficiency_ L2 - https://medlineplus.gov/bloodthinners.html DB - PRIME DP - Unbound Medicine ER -